Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific …
Over the last 12 months, insiders at Enhabit, Inc. have bought $526,487 and sold $5,586 worth of Enhabit, Inc. stock.
On average, over the past 5 years, insiders at Enhabit, Inc. have bought $672,474 and sold $5,586 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bolton Jeffrey (director) — $376,337. MCGUIGAN STUART M (director) — $264,300. Hoeflinger Erin (director) — $18,000.
The last purchase of 4,000 shares for transaction amount of $34,760 was made by Bolton Jeffrey (director) on 2024‑12‑12.
2024-12-12 | director | 4,000 0.0081% | $8.69 | $34,760 | -2.70% | |||
2024-12-10 | director | 15,000 0.0306% | $8.81 | $132,150 | -0.81% | |||
2024-11-12 | director | 3,000 0.006% | $7.60 | $22,800 | +1.58% | |||
2024-11-08 | director | 7,000 0.0139% | $7.77 | $54,377 | -2.03% | |||
2024-08-22 | director | 5,000 0.0099% | $8.01 | $40,050 | -2.93% | |||
2024-08-09 | director | 5,000 0.0098% | $8.29 | $41,450 | -6.74% | |||
2024-08-08 | director | 2,000 0.004% | $8.60 | $17,200 | -7.39% | |||
2024-05-17 | director | 10,000 0.0193% | $8.33 | $83,300 | -0.91% | |||
2024-05-14 | director | 2,000 0.004% | $9.00 | $18,000 | -9.28% | |||
2024-05-10 | director | 10,000 0.0197% | $8.24 | $82,400 | -1.08% | |||
2024-03-01 | Sale | EVP Clinical Excel. & Strategy | 634 0.0013% | $8.81 | $5,586 | -2.90% | ||
2023-05-26 | director | 2,000 0.004% | $11.61 | $23,220 | -7.53% | |||
2023-05-22 | director | 10,000 0.0198% | $11.98 | $119,800 | -12.08% | |||
2023-05-18 | EVP Clinical Excel. & Strategy | 10,000 0.02% | $11.99 | $119,900 | -10.68% | |||
2023-05-18 | director | 2,100 0.0042% | $11.82 | $24,822 | -10.68% | |||
2023-05-17 | director | 2,000 0.0039% | $11.80 | $23,600 | -10.81% | |||
2022-11-18 | director | 1,000 0.002% | $12.69 | $12,690 | -0.93% | |||
2022-11-09 | director | 2,000 0.004% | $12.75 | $25,500 | +0.08% | |||
2022-11-08 | director | 2,000 0.004% | $12.89 | $25,780 | -1.77% | |||
2022-11-08 | director | 426 0.0009% | $13.57 | $5,781 | -1.77% |
Bolton Jeffrey | director | 98144 0.1952% | $7.67 | 14 | 0 | <0.0001% |
Langham Ronald Leroy JR | EVP Clinical Excel. & Strategy | 57164 0.1137% | $7.67 | 1 | 1 | <0.0001% |
MCGUIGAN STUART M | director | 46810 0.0931% | $7.67 | 1 | 0 | |
Hoeflinger Erin | director | 30399 0.0605% | $7.67 | 3 | 0 | <0.0001% |
Jacobsmeyer Barbara Ann | President and CEO | 238442 0.4742% | $7.67 | 1 | 0 | +3.36% |
BlackRock | $93.2M | 15.95 | 8M | -1.17% | -$1.1M | <0.01 | |
Deerfield Management | $58.22M | 9.96 | 5M | 0% | +$0 | 0.14 | |
The Vanguard Group | $53.95M | 9.23 | 4.63M | -18.85% | -$12.53M | <0.01 | |
AREX Capital Management, LP | $28.12M | 4.81 | 2.41M | -0.03% | -$9,424.85 | 31.49 | |
State Street | $23.2M | 3.97 | 1.99M | -0.82% | -$190,920.20 | <0.01 |